In Brief: Abbott
Abbott: Expanded access program for protease inhibitor ritonavir will be managed by the Philadelphia-based CRO Medex. Abbott will be making ritonavir available to about 2,000 patients worldwide via a lottery set to begin in mid-January. AIDS patients with CD4 counts below 50 cells/mm3 who are over the age of 12 will be eligible for the lottery, with further information available at 1-800-414-AIDS...
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth